<DOC>
	<DOCNO>NCT01809912</DOCNO>
	<brief_summary>To investigate safety tolerability 28 day course intravenous ( IV ) MG1102 patient solid tumor standard therapy available .</brief_summary>
	<brief_title>Safety Study MG1102 Patients With Solid Tumors</brief_title>
	<detailed_description>This open-label , Dose Escalation Study , multicenter phase I study evaluate safety tolerability , determine pharmacokinetics , obtain preliminary information regard pharmacodynamics efficacy MG1102 subject solid tumor . Each subject receive dose MG1102 follow 6-day rest period . If initial dose tolerate , subject continue 21 day MG1102 administration ( 5 day treatment , 2 day treatment 3 week . ) Subjects tumor response stable disease , may continue therapy compassionate use . Study Duration : minimum 8 week</detailed_description>
	<criteria>18 year age old Solid tumor refractory conventional therapy subject tolerate conventional therapy Evaluable disease least one measurable tumor mass radiographic technique Life expectancy ≥3 month Suitable intravenous administration study medication Signed write informed consent Adequate bone marrow , renal , liver function Coagulation profile aPTT INR , ≤ 1.5 x ULN No evidence active Hepatitis B Hepatitis C infection Proteinuria &lt; 100 mg ECOG performance status ≤2 Female subject must agree use contraceptive measure Negative serum ßhCG Ability willingness comply study protocol Pregnant lactate woman Therapy systemic anticoagulant antithrombotic agentswithin 7 day prior first dose Hemoptysis within 3 month prior first dose Cytotoxic chemotherapy , immunotherapy , radiotherapy within 4 week prior first dose Surgery visceral biopsy within 28 day prior first dose Minor surgical procedure perform within 7 day prior first dose Prior exposure MG1102 Known history HIV With active bacterial infection and/or receive systemic antibiotic Current past diagnosis leukemia Known CNS metastases clinical evidence CNS Nonhealing wound within past 2 week Bleeding diathesis bleeding within 14 day prior enrollment Clinically significant thrombosis Nonmalignant GI bleeding , gastric stress ulceration , peptic ulcer disease History idiopathic hereditary angioedema History sickle cell hemolytic anemia Require hemoglobin , WBC , platelet transfusion support use hematopoietic growth factor within 2 week prior entry Uncontrolled hypertension History clinically significant renal disease History significant medical illness cardiac CNS disease within past 6 month Treatment investigational agent within long time frame either 5 halflives 30 day initiate study drug Medical psychiatric illness Recreational substance use psychiatric illness Known hypersensitivity MG1102 component formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>solid tumor</keyword>
</DOC>